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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the central 
nervous system (CNS), representing the most common CNS 
inflammatory disorder and the second leading cause of disability 
in young adults. In experimental autoimmune encephalomyeli-
tis (EAE), the animal model of MS, myelin-reactive pathogenic 
T helper (Th) cells enter the CNS at the level of pial vessels and 
are reactivated in the subarachnoid space by meningeal perivas-
cular macrophages (1) that allow pathogenic Th cells tissue entry 
and initiation of inflammation (2). Pathogenic Th cells induce, 
through granulocyte-macrophage colony-stimulating factor 
(GM-CSF), an inflammatory program in monocytes and their 
progeny, monocyte-derived dendritic cells (moDCs) (2, 3). In 
the CNS, moDCs function as antigen-presenting cells (APCs) to 
pathogenic Th cells, secreting polarizing cytokines such as IL-1, 
IL-23, IL-6, and TNF-α (4–7), and directly contribute to myelin 
and axonal loss via phagocytosis and the production of ROS and 
other neurotoxic mediators (3, 8).
Although available therapies for MS effectively target the 
recruitment of T cells from the periphery into the CNS (9), there is 
no conclusive evidence regarding their ability to target either the 
self-maintaining inflammatory cycle that occurs locally within the 
CNS or the pathogenic phenotype of CNS-infiltrating monocyte-
derived cells (MCs) (10).
Neural precursor cells (NPCs) have been previously studied 
as a therapeutic strategy for MS for their regenerative potential, 
and, more recently, for their neuroprotective and immunomod-
ulatory properties (11–14). NPCs express chemokine receptors 
and adhesion molecules that allow them, upon transplantation, 
to reach inflamed areas in the CNS (11, 15–17) and to release a 
variety of cytokines and neurotrophins that can inhibit the adap-
tive and innate immunity (18–20). While previous studies found 
intrathecal transplantation of NPCs to ameliorate EAE disease 
severity (14, 21, 22), the immunological mechanism underlying 
the therapeutic efficacy of NPCs delivered in the inflamed CNS 
still remains unknown.
In this work we investigated whether intrathecal NPC treat-
ment could directly interfere with the CNS-restricted crosstalk 
between pathogenic Th cells and inflammatory MCs. We found 
that NPC treatment impaired the accumulation of infiltrating MCs 
in the CNS and reduced EAE disability. In fact, NPCs limited the 
expression of cytokines required for the polarization of encephali-
togenic GM-CSF–producing Th cells. NPCs inhibited in vivo and 
in vitro DC differentiation and maturation, favoring a fate switch 
toward an antiinflammatory phenotype. We identified TGF-β2 as 
the primary factor secreted by NPCs for the observed therapeutic 
effect in the chronic phase of EAE.
In multiple sclerosis, the pathological interaction between autoreactive Th cells and mononuclear phagocytes in the CNS 
drives initiation and maintenance of chronic neuroinflammation. Here, we found that intrathecal transplantation of neural 
stem/precursor cells (NPCs) in mice with experimental autoimmune encephalomyelitis (EAE) impairs the accumulation of 
inflammatory monocyte-derived cells (MCs) in the CNS, leading to improved clinical outcome. Secretion of IL-23, IL-1, and 
TNF-α, the cytokines required for terminal differentiation of Th cells, decreased in the CNS of NPC-treated mice, consequently 
inhibiting the induction of GM-CSF–producing pathogenic Th cells. In vivo and in vitro transcriptome analyses showed that 
NPC-secreted factors inhibit MC differentiation and activation, favoring the switch toward an antiinflammatory phenotype. 
Tgfb2–/– NPCs transplanted into EAE mice were ineffective in impairing MC accumulation within the CNS and failed to drive 
clinical improvement. Moreover, intrathecal delivery of TGF-β2 during the effector phase of EAE ameliorated disease severity. 
Taken together, these observations identify TGF-β2 as the crucial mediator of NPC immunomodulation. This study provides 
evidence that intrathecally transplanted NPCs interfere with the CNS-restricted inflammation of EAE by reprogramming 
infiltrating MCs into antiinflammatory myeloid cells via secretion of TGF-β2.
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elination and axonal loss in the spinal cord at the end of follow-up 
(Figure 1, B–D). Interestingly, we found 2 weeks after treatment 
(40 dpi) a significant reduction of the inflammatory infiltrate 
areas (Figure 1E) and in particular of CD3+ T cells (Supplemen-
tal Figure 1A; supplemental material available online with this 
article; https://doi.org/10.1172/JCI92387DS1) and of IB4+ phago-
cytes (Supplemental Figure 1B) in the spinal cord of NPC-treated 
compared with PBS-treated mice. We further observed that NPC-
treated mice, compared with PBS-treated controls, already at this 
early time point, displayed a parallel reduction of both inflamma-
tion (IBA1+ areas) and demyelination (loss of MBP+ areas) in the 
spinal cord (Supplemental Figure 1, C and D). At this same time 
point, we observed that most transplanted GFP+ NPCs localized 
in the subarachnoid space of cerebellum, brainstem, and cervical 
spinal cord, with similar spatial distribution of infiltrating extrapa-
renchymal CD11b+ myeloid cells (Figure 2, A and B, and Supple-
mental Figure 2A). Transplanted NPCs were found in proximity 
to meningeal vessels and CD45+ perivascular inflammatory cells, 
Results
Intrathecal NPC transplantation ameliorates EAE by reducing 
inflammatory MCs in the CNS. To examine the capacity of NPC 
transplantation to inhibit the CNS-restricted inflammation occur-
ring in EAE, we first validated the therapeutic potential of intra-
thecal NPC injection in C57BL/6 mice immunized with myelin oli-
godendrocyte glycoprotein (MOG)35–55 peptide. One million NPCs 
in PBS (NPC-treated) or PBS alone (PBS-treated) was intrathe-
cally injected into the cisterna magna at the peak of disease sever-
ity, 4 days after clinical onset. We observed that NPC-treated mice 
displayed faster recovery and lower disability compared with EAE 
mice treated only with PBS (Figure 1A). At 1 month after treatment 
(60 days postimmunization [dpi]), NPC-treated mice showed sig-
nificantly lower neurological impairment, and at the end of the 
follow-up (80 dpi), NPC-treated mice showed either complete 
functional recovery or minor tail paralysis, while PBS-treated mice 
maintained an overt paresis of the hind limbs. Accordingly, NPC-
treated mice displayed a lower lesion burden measured as demy-
Figure 1. Intrathecally administered NPCs ameliorate chronic EAE. (A) Top: Clinical scores of EAE mice treated at the peak of the disease (4 days after 
the clinical onset, arrow) with intrathecal injection (into cisterna magna) of either NPCs (red dots) or PBS (black dots), n = 20 mice per group. Each point 
represents the mean ± SEM; 70 to 82 dpi, 2-way ANOVA with Bonferroni’s post-test, *P ≤ 0.05. Bottom: Linear regression curves of clinical score from the 
day of treatment with either NPCs or PBS until 60 or 80 dpi. Dashed lines indicate 95% CI. **P ≤ 0.01; ***P ≤ 0.001. (B–D) Quantification and represen-
tative images of spinal cord demyelination (Luxol fast blue staining) (B) and axonal loss quantified on Bielschowsky silver staining (C; at bottom right, 
high-magnification insets, ×100) and immunohistochemistry for neurofilaments (NF) (D) at 80 dpi in PBS-treated (black bars) versus NPC-treated (white 
bars) EAE mice (n = 15 sections per mouse, 3–6 mice per group). (E) Quantification and representative images of inflammatory infiltrates (H&E staining) 
at 30 dpi in PBS-treated (black bars) versus NPC-treated (white bars) EAE mice (n = 12–20 sections per mouse, 3 mice per group). Data are mean ± SEM and 
represent the percentage area of damage over total section area. *P ≤ 0.05, **P ≤ 0.01, unpaired t test. Scale bars: B–E, 100 μm.
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treated EAE mice (Figure 3, A–C). Microglia (CD45loCD11b+Ly6G–
Ly6C–) were not quantitatively altered after NPC treatment (Fig-
ure 3, A and D), but displayed lower expression of MHC-II (Figure 
3, E and F), suggestive of a lower activation state.
NPC treatment hampers the effector phase of EAE. The accu-
mulation of myeloid cells in the CNS during the effector phase 
of EAE relies on the ability of CNS-invading Th cells to secrete 
GM-CSF (2, 3). NPC-transplanted mice had significantly lower 
frequencies of GM-CSF+ cells in CNS-infiltrating Th1 and Th17 
cells (Figure 4A) as well as in total CD4+ T cells (Figure 4B). No 
significant difference between NPC- and PBS-treated mice, nei-
ther in the frequency of FoxP3+ Tregs nor in the level of FoxP3 
expression by CNS-infiltrating CD4+ T cells, was observed (Fig-
ure 4, C and D). Consistently, CD4+ T cells in the CNS showed 
significantly lower expression of transcripts related to Th17 
pathogenicity (24), such as Il23r, Rorc, Tbx21, Il22, Cxcl3, and 
Csf2, in NPC-treated mice (Figure 4E). Furthermore, GM-CSF 
levels were significantly reduced in the hindbrain and cervical 
spinal cord of NPC-treated mice (Figure 4F).
The capacity of autoreactive Th cells to secrete GM-CSF 
depends on the production of proinflammatory cytokines by 
moDCs (2, 3, 7, 25). Seven days after transplantation, we found 
including CD4+ T cells, CD11b+ myeloid cells, MHC class II+ cells, 
and CD11c+ DCs (Figure 2, C–F). Transplanted NPCs retained an 
undifferentiated phenotype up to the end of follow-up, at 80 dpi, 
displaying only in low percentage markers for neuronal (β-tubulin 
III, β-tub III+), oligodendroglial (oligodendrocyte lineage tran-
scription factor 2, Olig2+), or astroglial lineage (glial fibrillary 
acidic protein, GFAP+) (Supplemental Figure 2, B–D and G). Fur-
ther, transplanted NPCs expressed the stem cell marker nestin 
and the proliferation marker Ki-67 (Supplemental Figure 2, E and 
F). Notably, intrathecally transplanted GFP+ NPCs were detected 
only in the CNS of NPC-transplanted mice (Supplemental Figure 
3, A and B), while NPCs were found neither in peripheral organs 
(Supplemental Figure 3, C–E) nor in secondary lymphoid organs 
(Supplemental Figure 3, F–H).
To better investigate the mechanism regulating the clinical 
and pathological recovery induced by transplanted NPCs, we per-
formed flow cytometry analysis of CNS-resident and infiltrating 
inflammatory cells of EAE mice 7 days after NPC or PBS treatment. 
We observed a significant reduction in frequency and cell number of 
inflammatory MCs (CD45hiCD11b+Ly6G–Ly6C+CD11c+MHC-II+) 
(23) as well as a trend of reduction of infiltrating lymphoid cells 
(CD45hiCD11b–) in the CNS of NPC-treated compared with PBS-
Figure 2. Transplanted NPCs distribute in the subarachnoid space within the inflammatory infiltrates. (A and B) Representative 3D reconstruction of 
the relative distribution of transplanted NPCs (GFP+ in green) and CD11b+ inflammatory cells (in red) within the hindbrain (A, rostral and caudal view) and 
the cervical spinal cord (B) (outlined in gray), the cerebral aqueduct and IV ventricle (outlined in yellow), in an NPC-treated mouse at 7 days after trans-
plantation, obtained from a total of n = 33 sequential stereology sections. (C–F) Representative immunofluorescence images of intrathecally transplanted 
NPCs (GFP+ in green, arrowheads in the magnified insets, shown below, of the above dashed boxes) that localize in the meningeal perivascular spaces of 
the spinal cord and brainstem, often detected in proximity to von Willebrand factor–positive (vWF+) endothelial cells (white in C), to CD45+ blood-derived 
leukocytes (red in C), to perivascular infiltrating CD11b+ myeloid cells (red in D), to CD4+ T cells (white in D), and to MHC-II+ as well as CD11c+ local APCs (red 
in E and F, respectively). Nuclei are stained by DAPI (blue). Scale bars: C–F, 25 μm.
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(NCM) or control DC culture medium (DCM) during stimu-
lation with CD40L, mimicking T cell interaction with APCs. 
BMDCs exposed to NCM expressed lower levels of MHC-II and 
of the costimulatory molecules CD80 and CD86 compared with 
BMDCs in DCM (Figure 6, A and D). Cytokine profiling showed 
that BMDCs exposed to NCM produced a significantly lower 
amount of polarizing cytokines, including TNF-α, IL23p19, IL-6, 
and IL12p70 and chemokines such as CXCL10, CXCL1, and 
G-CSF (Figure 6B). We further confirmed the inhibitory effect of 
NCM on IL-23 and TNF-α production by ELISA (Figure 6C) and 
quantitative PCR (Figure 6D). Finally, we assessed the ability of 
BMDCs exposed to NCM during CD40L stimulation to reacti-
vate CD4+ T cells from MOG35–55 peptide–immunized 2D2 mice. 
Conditioning of BMDCs with NCM during CD40L stimulation 
decreased their ability to induce the production of GM-CSF in 
Th1 and Th17 cells (Figure 7).
significantly lower expression of Il23a and Tnfa transcripts in the 
CNS inflammatory infiltrate of NPC-treated mice (Figure 5A). 
Moreover, IL23p19 protein levels were significantly reduced in the 
CNS of NPC-transplanted mice (Figure 5B). Accordingly, cytokine 
profiling of CNS tissues revealed also decreased levels of IL-1β 
and TNF-α and of IL-23–related factors such as G-CSF, CXCL1, 
and IL-17A (Figure 5C). These findings support the idea that NPC 
treatment dampens the production of polarizing cytokines by 
inflammatory MCs, which in turn reduce GM-CSF production and 
the pathogenic potential of CNS-invading Th cells.
NPC-secreted factors inhibit maturation of DCs and their 
capacity to trigger GM-CSF production in myelin-reactive Th cells. 
We hypothesized that an NPC-secreted factor could inhibit the 
antigen-presenting and proinflammatory properties of myeloid 
cells. To investigate this hypothesis, we exposed in vitro bone 
marrow–derived DCs (BMDCs) to NPC-conditioned medium 
Figure 3. NPC transplantation reduces the accumulation of inflammatory MCs and the activation of microglia during the effector phase of EAE. (A–D) 
Flow cytometry of CNS leukocytes from PBS- and NPC-treated EAE mice, assessed at day 7 after transplantation. Frequencies and total cell number of 
CNS-infiltrating lymphoid cells (LCs; CD45hiCD11b–) and inflammatory MCs (CD45hiCD11b+Ly6G–Ly6ChiCD11c+MHC-II+) are shown in the plots (A) and quanti-
fied in the graphs (n = 4–5 mice per group) (B and C). Frequencies and total cell number of CNS-resident microglia (CD45intCD11b+Ly6G–Ly6C–) are shown in 
the plots (A) and quantified in the graphs (n = 4–5 mice per group) (D). (E and F) Level of MHC-II on microglia in PBS-treated (black line) and NPC-treated 
EAE mice (red line) at day 7 after transplantation is shown in the histogram (mean fluorescence intensity, MFI) (E) and quantified in the graph (n = 4 
mice per group) (F). Black bars, PBS-treated mice; white bars, NPC-treated mice. Data are mean ± SEM and are representative of 2 independent experi-
ments. *P ≤ 0.05, unpaired t test.
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Unsupervised hierarchical clustering clearly separated NCM-
treated mDC from control mDC, both at the early (6 hours) and at 
the late (18 hours) time point (Figure 8B). Subclustering analysis at 
each time point highlighted subsets of genes shared only between 
mDC-NCM and iDCs, suggesting an impairment of the CD40L-
induced maturation by NPC-secreted factors (Figure 8B). How-
ever, the exposure to NCM during CD40L stimulation instructed 
in DCs a specific gene expression signature, demonstrating the 
induction of an alternative program of activation/differentiation.
Indeed, gene ontology analysis identified enriched functional 
groups associated with metabolic processes (Arg1, Arg2, ferro-
portin-1), macromolecule biosynthesis, regulation of transcrip-
tion (Cbx5 and Itch), and programmed cell death in mDC-NCM 
at the early time point (Figure 8C). Genes related to oxidative 
stress and apoptosis resistance, such as Ak2, Tgm2, and Smarca2 
(26, 27), were upregulated whereas proapoptotic genes such as 
In conclusion, NPC-secreted factors inhibit in vitro the capac-
ity of DCs to induce GM-CSF–producing pathogenic Th cells.
NPC-secreted factors guide transcriptional reprogramming of 
inflammatory DCs toward an alternative antiinflammatory activa-
tion. We next sought to dissect the sequence of molecular events 
triggered by NPCs that induces immunomodulation in inflam-
matory myeloid cells. To follow over time the dynamic changes 
induced by NPCs in BMDCs, we performed gene expression pro-
filing on BMDCs after 6 and 18 hours of CD40L stimulation in the 
absence (mDC) or presence of NCM (mDC-NCM). WT unstimu-
lated immature DCs (iDCs) were used as reference group to iden-
tify maturation-related transcripts (Figure 8A).
Bioinformatics analysis identified 2 sets of unique genes that 
were differentially regulated between mDC and mDC-NCM after 
6 or 18 hours in culture with a significance threshold of P ≤ 0.01 
(Figure 8A and Supplemental Table 1).
Figure 4. NPC transplanta-
tion dampens the pathogenic 
signature of the CNS-infiltrating 
Th cells. (A and B) Production of 
GM-CSF by CNS-infiltrating Th1 
(CD45hiCD3+CD4+IFN-γ+) and Th17 
cells (CD45hiCD3+CD4+IL-17A+) in 
EAE mice 7 days after PBS or NPC 
treatment as analyzed by flow 
cytometry. Frequency of GM-CSF+ 
Th1, GM-CSF+ Th17, and total GM-
CSF+ Th cells are shown in the plots 
(A) and quantified in the graph  
(n = 4 mice per group) (B). (C) Fre-
quency of FoxP3+ CNS-infiltrating 
CD4+ T cells (CD45hiCD11b–CD4+) in 
PBS- and NPC-treated EAE mice at 
the same time point as A is shown 
in plots and graph (n = 4 mice per 
group). (D and E) Expression of 
FoxP3 (D) and Rorc, Il23r, Tbet, Il22, 
Csf2, and Cxcl3 (E) in CD45hiCD11b–
CD4+ Th cells sorted from the CNS 
of PBS- and NPC-treated EAE mice 
at the same time point, relative 
value to PBS-treated mice (n = 4 
mice per group). (F) GM-CSF quan-
tification by ELISA in hindbrain and 
cervical and dorsal spinal cord (SC) 
tissues of PBS- and NPC-treated 
EAE mice at 7 days after transplan-
tation (n = 6 mice per group). Black 
bars, PBS-treated mice; white bars, 
NPC-treated mice. Data are mean  
± SEM and are representative of  
2 independent experiments.  
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
unpaired t test.
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Tnfrsf6 (Fas) were downregulated in mDC-NCM. In addition, 
NCM induced in DCs transcripts related to the alternative or anti-
inflammatory phenotype, such as Arg1, Maf, Itch, Stab1, and Tgm2 
(28–32). Accordingly, mDC-NCM also upregulated the expression 
of Ddx21, which is required for the induction of S100A9 (33), an 
immaturity marker of myeloid-derived suppressor cells (MDSCs) 
(ref. 34; Figure 8, B and E; and Supplemental Table 1). At 18 hours, 
gene ontology analysis of NCM-regulated genes confirmed the 
NCM-induced shift of mDC toward an antiinflammatory activa-
tion. Indeed, NCM-treated mDC had a significantly lower expres-
sion of genes encoding proinflammatory chemokines (Ccl1, Ccl2, 
Ccl3, Ccl7, Ccl8, Cxcl2) (3, 35), positive regulators of cytokine 
production (CD36, Il33, Clec9a, and Clec5a) (36–39), and phago-
cytosis-related genes (Ptx3, Elmo2, Clec7a) (ref. 3 and Figure 8, B, 
D, and F). Conversely, NCM induced the antiinflammatory mol-
ecules Hspa1a, which impairs the stimulatory capacity of moDCs 
(40), and Il1r2, the IL-1 decoy receptor that blocks IL-1 signaling 
in inflammatory macrophages (41) and the NF-κB inhibitor Ascc1 
(ref. 42; Figure 8, B, D, and F; and Supplemental Table 1).
Transcription factor analysis of early (6 hours) NCM-regulated 
genes showed an enrichment in positively regulated transcripts 
controlled by c-Myc, a master regulator in macrophage alterna-
tive activation (43, 44), and c/EBPβ, which is the main regulator of 
MDSC differentiation (ref. 45 and Supplemental Figure 4A). At the 
later time point (18 hours), many negatively NCM-regulated tran-
scripts were enriched in genes controlled by PU.1 (46) and NF-κB1, 
both pivotal in DC differentiation and maturation (Supplemental 
Figure 4B, Supplemental Table 2, and refs. 46, 47).
When we compared the differentially expressed genes of 
CD40L-induced maturation in the absence (iDCs vs. mDC) or 
presence of NCM (iDCs vs. mDC-NCM), we identified pathways 
only modulated during the maturation induced in the presence of 
NPC-secreted factors. The pathways included at 6 hours the anti-
apoptotic TNFs/NF-κB/BCL-2 path-
way and NFAT in immune response 
(Supplemental Figure 5A), and at 18 
hours IL-4–induced regulators, p53 
signaling, NO synthesis and signaling, 
Fas signaling, and TGF-β–dependent 
activation, and were associated with 
an alternative activation of DCs (Sup-
plemental Figure 5B).
Specifically, among early NCM-reg-
ulated genes, Rad51 (48) and Arhgap15 
(49), known to be inhibited by TGF-β, 
were downregulated, while Arg1, which 
is induced by TGF-β (ref. 50; Figure 8, A 
and E; and Supplemental Table 1), was 
increased. Similarly, CD36 and Il33, 
both inhibited by TGF-β, were signifi-
cantly downregulated in mDC-NCM at 
18 hours (ref. 51; Figure 8, B, D, and F; 
and Supplemental Table 1).
We therefore investigated whether 
NPCs could influence myeloid cell dif-
ferentiation and activation also in vivo 
and possibly through TGF-β signaling 
during EAE. To this end, MOG35–55-immunized EAE mice were 
injected, at the peak of the disease, with 106 NPCs or vehicle. At 
7 days after transplantation, CNS-infiltrating MCs were FACS-
sorted (Figure 9A) and mRNA was extracted. Next-generation 
sequencing was performed, and genome-wide profiles were gen-
erated and compared between MCs isolated from the CNS of 
NPC-treated animals and PBS-treated animals in EAE. We identi-
fied 610 genes that were differentially expressed with the signifi-
cance threshold of P ≤ 0.01 (Figure 9B and Supplemental Table 3). 
Hallmark gene set enrichment analysis confirmed the modulation 
of metabolic processes and of several immunological pathways, 
including TGF-β signaling, the IFN response, and genes upregu-
lated by ROS, in MCs from NPC-treated mice (Figure 9, C and D). 
In line with in vitro data, transcription factor analysis found c-Myc 
and CREB1 (Supplemental Figure 6 and Supplemental Table 4), 
master transcription factors for the alternative activation of mac-
rophages (43, 52), as main regulators of NPC-induced gene signa-
ture in CNS-infiltrating MCs.
Overall these findings suggest that NPC-secreted factors 
skew the inflammatory differentiation program of MCs toward 
an alternative/antiinflammatory activation (53), possibly through 
TGF-β signaling, both in vitro, during DC activation, and in vivo, 
in the inflamed CNS.
TGF-β2 mediates the inhibitory effect of NPCs on DC matu-
ration. We next focused on identifying the secreted factor(s) 
responsible for the observed immunomodulatory effects of NPCs 
on inflammatory DCs.
First, we observed that NCM inhibits the production of IL-23 
by CD40L-stimulated BMDCs in a dose-dependent manner (Sup-
plemental Figure 7A). To investigate the nature of the secreted fac-
tor, NCM frozen at –20°C was thawed and then filtered through 
a 0.1-μm filter (Supplemental Figure 7B). The process did not 
alter NCM inhibitory activity, indicating that the factor is neither 
Figure 5. NPC transplantation impairs the production of polarizing cytokines by CNS-infiltrating APCs. 
(A) Expression of Il23 and Tnf in CNS leukocytes isolated from EAE mice at 7 days after PBS or NPC treat-
ment, relative value to PBS-treated mice (n = 3 mice per group). Data are representative of 2 independent 
experiments. (B) ELISA for IL23p19 in hindbrain and cervical and dorsal spinal cord tissues from PBS- and 
NPC-treated EAE mice obtained at the same time point as A (n = 3 mice per group). Data are representa-
tive of 2 independent experiments. (C) Cytokine profile in hindbrain tissues of PBS- and NPC-treated mice 
obtained at the same time point as A. Hindbrain tissue lysates were analyzed for expression of various 
cytokines by Luminex-based assay (n = 10 mice per group). Black bars, PBS-treated; white bars, NPC- 
treated. Data are mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, unpaired t test.
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released as exosome nor as microvesicle. Further, size fraction-
ation demonstrated that the inhibitory activity of NCM on DC 
maturation was absent when the secretome of ≤3 kDa was used, 
excluding small molecules as possible mediators of NCM effect 
(Supplemental Figure 7C). However, proteinase K treatment or 
heat inactivation (80°C) abolished NCM activity (Supplemental 
Figure 7D), indicating that the active secreted factor was a protein.
Since transcriptome analyses suggested the involvement of 
TGF-β signaling in the modulation of myeloid inflammatory cells 
by NPCs (Figures 8 and 9), we focused our investigation on ele-
ments of the TGF-β family, morphogenic factors with known 
immunomodulatory and tolerogenic effects on both T cells and 
DCs (54–58). NPCs release in vitro TGF-β2 and are equipped to 
promote activation of latent TGF-β2, via matrix metalloproteinas-
es and thrombospondins (Figure 10, A and B). We further showed 
that BMDCs express receptors to transduce TGF-β signaling (Fig-
ure 10A). Supplementation of BMDC culture with TGF-β2 result-
ed in marked and dose-dependent inhibition of IL-23 secretion by 
CD40L-stimulated BMDCs (Figure 10C). Consistently, pharma-
cological inhibition of TGF-β signaling with SB431542, the tyro-
sine kinase inhibitor of TGF-β receptor 1 (TGFBRI), or with ITD1, 
which induces the proteosomal degradation of TGF-β receptor 2 
(TGFBRII) (59), reverted almost completely the effect of NCM on 
DCs (Figure 10, D and E).
Furthermore, we confirmed that TGF-β2 signaling on 
BMDCs was required for NPC immunomodulation, since the 
Figure 6. NPC-secreted factors impair the maturation of BMDCs. (A) Levels of MHC-II, CD86, and CD80 on CD40L-stimulated BMDCs in the absence or 
presence of NCM for 48 hours. Gray lines represent immature unstimulated BMDCs (iDCs), black lines BMDCs matured in control medium (mDC), red 
lines CD40L-matured BMDCs in the presence of NCM (mDC-NCM), and filled gray histograms fluorescence minus one controls (n = 3 samples per group). 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 1-way ANOVA with Bonferroni’s post-test. (B) Unsupervised clustering of cytokine profile in supernatants of CD40L-
matured BMDCs in the absence (mDC) or presence of NCM (mDC-NCM). Supernatants were collected after 48 hours in culture, 0.2-μm-filtered, and ana-
lyzed for expression of various cytokines by Luminex-based assay (individual samples are shown). (C) Protein levels of indicated cytokines in iDCs, mDC, 
and mDC-NCM, validated by ELISA (n = 3 samples per group). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 1-way ANOVA with Bonferroni’s post-test. (D) Expression 
of Cd80, Cd86, Il23a, Il12b, Tnf, Il1b, and Il6 in BMDCs treated as in B for 18 hours, relative value to BMDCs matured in control medium (n = 3 samples per 
group). *P ≤ 0.05, **P ≤ 0.01, unpaired t test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 1-way ANOVA with Bonferroni’s post-test. Gray bars, iDCs; black bars, 
mDC; white bars, mDC-NCM. Data are mean ± SEM and are representative of 2 independent experiments.
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in EAE mice. Tgfb2–/– eNPCs distributed within the perivascu-
lar space of the leptomeningeal vessels nearby inflammatory 
CD11b+ cells, similarly to WT eNPCs (Tgfb2+/+ eNPCs) (Figure 
11, A and B). However, Tgfb2–/– eNPCs were not effective in 
inducing the clinical amelioration observed after WT eNPC 
transplantation (Figure 11C). Moreover, Tgfb2–/– eNPCs did not 
hamper demyelination, axonal damage, and inflammatory infil-
tration due to EAE (Figure 11, D–F). Consistently, Tgfb2–/– eNPCs 
failed to prevent accumulation of the inflammatory MCs in the 
CNS of EAE mice (Figure 11G) and upregulation of MHC-II on 
microglia (Figure 11H). Accordingly, WT NPC treatment, unlike 
Tgfb2–/– eNPC or PBS treatment, significantly increased the fre-
quency of SMAD2 phosphorylation in CNS-infiltrating CD11b+ 
myeloid cells, thus supporting that the therapeutic effect of 
NPCs acts through the activation of the TGF-β pathway in CNS-
infiltrating MCs (Figure 11I).
We tried to recapitulate the therapeutic effect of NPCs via 
intrathecal injection in the cisterna magna of a lentiviral vec-
tor expressing TGF-β2. The resulting increased expression of 
TGF-β2 at the peak of EAE severity within the CNS was sufficient 
to induce clinical amelioration in EAE mice, when compared with 
control mice receiving GFP-expressing control lentiviral con-
struct (Supplemental Figure 10).
Altogether our data indicate that TGF-β2 production by trans-
planted NPCs is necessary for NPC immunomodulatory effect on 
pathogenic properties of myeloid cells in vitro and in vivo and is 
nonredundant for NPC therapeutic effect in EAE.
Furthermore, increasing the intrathecal levels of TGF-β2 at the 
peak of EAE disease severity resulted in accelerated clinical recovery.
Discussion
In this study we provide evidence that intrathecally injected NPCs 
interfere with the pathogenic properties of CNS-infiltrating MCs 
via the secretion of the immunomodulatory cytokine TGF-β2.
genetic ablation of TGFBRII on CD11c+ BMDCs, obtained from 
CD11c-Cre+Tgfbr2fl/fl mice (60, 61), made DCs insensitive to the 
NCM effect (Figure 10F).
To investigate the role of TGF-β2, we generated NPCs from 
Tgfb2tm1Doe mice (Tgfb2–/–), which constitutively lack functional 
TGF-β2 (62). Given the perinatal lethality of homozygous mutant 
mice (62), NPCs were derived from E15.5 Tgfb2–/– mouse embryos 
(embryonic NPCs [eNPCs]). Tgfb2–/– eNPCs were not affected in 
their viability and proliferative capacity in vitro (Supplemental 
Figure 8A); they efficiently differentiated in vitro into astrocytes 
and oligodendrocytes, producing slightly more neurons compared 
with WT (Tgfb2+/+) eNPCs (Supplemental Figure 8, B–E). Impor-
tantly, Tgfb2–/– eNPCs maintained the expression of CD44, integ-
rin α4, and CXCR4 (Supplemental Figure 8F), adhesion molecules 
crucial for the homing and persistence of transplanted NPCs in 
the CNS during EAE (11).
The expression of TGF-β2 in eNPCs derived from heterozy-
gous and homozygous Tgfb2tm1Doe mice was reduced in an allele-
dosage manner at both the mRNA and the protein level (Figure 
10, G and H). In line with this, NCM obtained from Tgfb2–/– eNPCs 
had significantly lower inhibitory activity on IL-23 production by 
BMDCs (Figure 10I).
Overall, these data pointed to TGF-β2 as the main driver of 
the immunomodulatory effect of NPC on BMDC differentiation 
and maturation.
TGF-β2 is nonredundant for the therapeutic effect of NPCs in 
chronic EAE. Upon intrathecal transplantation of NPCs in EAE 
mice, we observed that NPCs secrete TGF-β2 in vivo (Supplemen-
tal Figure 9, A and B) and that adjacent CNS-infiltrating CD11b+ 
cells were positive for phosphorylated SMAD2 (p-SMAD2), sug-
gestive of an activation of the TGF-β pathway in the MCs induced 
by NPC treatment (Supplemental Figure 9C).
To understand the therapeutic relevance of TGF-β2 pro-
duced by NPCs, we intrathecally transplanted Tgfb2–/– eNPCs 
Figure 7. BMDCs matured in the presence of NPC-secreted factors fail to polarize MOG35–55-specific CD4+ T cells toward GM-CSF production. (A and B) Fre-
quency of Th1 (GM-CSF+IFN-γ+) and Th17 (GM-CSF+IL-17+) among 2D2 CD4+ T cells stimulated with MOG35–55 in the presence of BMDCs cultured as described 
in Figure 6 are shown in the plots (A) and graphs (B) (n = 3–4 samples per group). *P ≤ 0.05, ***P ≤ 0.001, 1-way ANOVA with Bonferroni’s post-test. Gray 
bars, iDCs; black bars, mDC; white bars, mDC-NCM. Data are mean ± SEM and are representative of 2 independent experiments.
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Figure 8. NPC-secreted factors redirect the transcriptional program of BMDC 
maturation toward an alternative activation. (A) Workflow of microarray 
gene expression analysis at 6 and 18 hours showing the differential expres-
sion between control medium (mDC) and NCM-cultured BMDCs (mDC-NCM) 
during CD40L-induced maturation. (B) Unsupervised hierarchical clustering of 
expression profiles of 130 and 175 differentially modulated genes with ≥1.3-
fold change and a P ≤ 0.01 in mDC-NCM and mDC at 6 and 18 hours in culture, 
respectively, compared with the expression profiles of the same transcripts in 
unstimulated BMDCs (iDCs). Dashed lines indicate subclusters of genes that 
in mDC-NCM return to the expression levels observed in iDCs. (C) Gene ontol-
ogy enrichment of differentially modulated genes between mDC-NCM and 
mDC at 6 and 18 hours. The gray scale indicates the statistical significance 
(FDR ≤0.05). (D) Color-coded ratio of mDC-NCM over mDC showing NCM-
regulated genes at 18 hours, clustered to the indicated pathways (blue means 
downregulation, red upregulation). Significance is shown alongside.  
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, unpaired t test. (E and F) Quantitative 
PCR validation of indicated differentially expressed genes in mDC-NCM com-
pared with mDC at 6 (E) and 18 hours (F); the expression is relative to mDC  
(n = 3 samples per group). *P ≤ 0.05, **P ≤ 0.01, unpaired t test.
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Figure 9. NPC treatment alters the gene expres-
sion signature of CNS-infiltrating inflammatory 
MCs in EAE. (A) Cohorts of 4–7 MOG35–55-immunized 
C57BL/6 mice intrathecally treated with either 
PBS or NPCs at the peak of the disease (2–4 days 
after clinical onset). At 7 days after transplanta-
tion, CNS tissues were pooled and CNS-infiltrating 
MCs were FACS-sorted according to the phenotype 
CD45hiLy6G–CD11b+Ly6ChiMHC-II+. Sorting strategy 
used for 3 independent FACS sorting experiments 
is shown. (B) Next-generation sequencing was 
performed on RNA extracted from sorted cells of 3 
independent experiments and respective CNS har-
vests. Six hundred ten genes that are significantly 
altered in 3 different statistical tests to a minimum 
significance threshold of P ≤ 0.01 are shown in the 
heatmap. (C) Volcano plot showing the fold change 
and significance of genes in MCs from PBS- versus 
NPC-treated EAE mice. (D) Bipartite graph of func-
tional enrichment analysis using hallmark data set 
for NPC treatment obtained by Cytoscape software 
(http://www.cytoscape.org/). Black and gray nodes 
represent enriched pathways with sizes correspond-
ing to FDR-adjusted enrichment P value (P ≤ 0.05). 
Red dots represent upregulated genes and blue 
dots downregulated genes, whereas the dot size 
indicates significance (P ≤ 0.01).
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tion of leukocytes is abolished, despite the initial CNS invasion 
by CD4+ T cells (2, 69, 70).
Interestingly, we found that, early after treatment, NPC-
injected EAE mice have reduced GM-CSF–producing patho-
genic Th cells infiltrating the CNS and lower expression of genes 
related to Th17 pathogenic signature, including Il23r, essential 
for the maturation of effector Th17 cells (24, 71–74). The acqui-
sition of Th17 pathogenic potential is a multistep process that 
starts in secondary lymphoid organs and can be completed only 
in the target tissue (75). MCs act as blood-borne APCs, sustain-
ing encephalitogenic Th cell reactivation and full differentiation 
within the inflamed CNS through the secretion of proinflamma-
tory cytokines (4, 5, 7, 63). Our data reveal that NPC treatment 
reduces in the CNS the burden of polarizing cytokines, including 
IL-1 and IL-23, required for the generation of pathogenic GM-
CSF–producing Th cells.
Considering that intrathecally transplanted NPCs maintain an 
undifferentiated phenotype, we hypothesized a paracrine effect 
of NPCs, acting via the secretion of cytokines, growth factors, or 
morphogens to modulate infiltrating myeloid inflammatory cells. 
Accordingly, NPC-secreted factors recapitulated in vitro the NPC 
inhibitory effect on the ability of DCs to secrete polarizing cyto-
We initially observed that intrathecally transplanted NPCs 
distribute within the leptomeningeal perivascular space of 
EAE mice, close to myeloid infiltrating cells and pathogenic Th 
cells, and maintain mainly an undifferentiated phenotype. This 
localization within the leptomeninges, an important site for the 
reactivation of autoaggressive Th cells by meningeal perivascu-
lar macrophages (1), allows NPCs to impact on CNS-restricted 
immunopathogenic events.
Indeed, intrathecal transplantation of NPCs reduces during 
overt EAE the accumulation within the CNS of inflammatory 
infiltrating cells and in particular of monocytes and their prog-
eny, MCs, and also restrains microglia activation, leading to a 
long-term amelioration of disease-related disability. Inflamma-
tory Ly6Chi-monocyte-derived DCs are indeed a key pathogenic 
myeloid cell population in the CNS of EAE mice (63, 64). EAE 
severity correlates with the number of monocytes in the spinal 
cord, and mice in which monocytes are inhibited from entering 
the CNS are protected against EAE development (35, 65, 66). 
The reduced infiltration of MCs in the CNS of NPC-treated mice 
and the evidence of lower microglia activation have been simi-
larly observed in GM-CSF–depleted EAE mice (2, 67, 68). In fact, 
mice lacking GM-CSF do not develop EAE, since the accumula-
Figure 10. NPCs inhibit BMDC maturation in vitro via TGF-β2. (A) Color-coded expression heatmap of selected TGF-β family growth factors and TGF-β 
activating enzymes in NPCs (left) and of their relative receptors on mDC (CD40L-stimulated BMDCs; right). Data are represented as ΔCt over Gapdh (note 
that a higher ΔCt denotes a lower expression level). (B) ELISA for TGF-β2 performed on NCM from NPCs cultured in DC medium for 2, 6, 24, and 48 hours. 
(C) Quantification by ELISA of IL23p19 secreted in the supernatant of mDC cultured either in control medium (black bar) or in the presence of recombinant 
TGF-β2 at increasing concentrations (gray bars). (D and E) Quantification by ELISA of IL23p19 secreted by mDC cultured either in NCM alone (white bar) or 
in the presence of the TGFBRI tyrosine kinase inhibitor SB431542 (gray bars) (D) or with the TGFBRII inhibitor ITD1 (gray bar) (E). (F) Quantification by ELISA 
of the IL23p19 secreted by mDC from control littermates CD11c-Cre+Tgfbr2WT/WT (white bar) and CD11c-Cre–Tgfbr2fl/fl (gray bar) versus CD11c-Cre+Tgfbr2fl/fl 
(gray striped bar) mDC lacking TGFBRII in CD11c+ cells. Data in D-F are fold induction (FI) relative to mDC matured in control medium subjected to the same 
treatment. (G) Expression of Tgfb2 mRNA in WT (Tgfb2+/+), Tgfb2+/–, and Tgfb2–/– eNPCs cultured for 48 hours in DCM relative to WT NPCs. (H) TGF-β2 
protein quantification by ELISA secreted by Tgfb2+/+, Tgfb2+/–, and Tgfb2–/– eNPCs cultured for 48 hours in DC medium. (I) IL23p19 production (measured by 
ELISA) by mDC cultured in NCM from Tgfb2+/+ (white bar) and Tgfb2–/– (gray bar) eNPCs. Data are FI relative to mDC matured in control medium. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, 1-way ANOVA with Bonferroni’s post-test (C, D, F, H, and I); *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001, unpaired t test 
(E, G). Data are mean ± SEM and are representative of at least 2 independent experiments.
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at least 2 types of signals: factors that expand myeloid precursors 
such as M-CSF, G-CSF, and GM-CSF (79), followed by factors 
that activate immune-regulatory programs. Besides classic Th2 
cytokines (e.g., IL-4 and IL-13), chemokines (e.g., CCL5, CXCL12, 
and CX3CL1) as well as growth factors and noncanonical chemo-
tactic peptides (e.g., VEGF-α, TGF-β, basic FGF, and antimicro-
bial peptides) (80) can contribute as “second signal” to monocyte 
recruitment and tolerogenic macrophage differentiation (45). In 
our study of intrathecal NPC treatment during the effector phase 
of EAE, we hypothesized that the inflammatory milieu provides 
abundant proliferative stimuli to the CNS-infiltrating myeloid 
compartment, while NPC-secreted TGF-β2 could impart the 
antiinflammatory signal. TGF-β signaling is necessary to prevent 
autoimmunity (81), and the signaling through the TGFBRs in DCs 
is a prerequisite to control EAE autoimmune response (82). More-
over, TGF-β limits at the site of inflammation the differentiation of 
highly mature DCs as a means of restricting Th17 cell differentia-
tion and controlling autoimmunity (83).
In our experimental setting, TGF-β2 was found to be the most 
expressed among TGF-β family members in NPCs, and gain- and 
loss-of-function experiments demonstrated that TGF-β2 recapitu-
lates the immunomodulatory effect of NPCs in vitro. In support of 
the role of TGF-β2, the transplantation of TGF-β2–deficient NPCs, 
during the EAE effector phase, failed to induce the expected clini-
cal and neuropathological improvement, since it did not prevent 
the accumulation of MCs in the CNS. This finding indicates that 
TGF-β2 is required for efficient immunomodulation by transplant-
ed NPCs, since a different source of NPCs (eNPCs), lacking only 
TGF-β2, did not display a therapeutic effect in our experimental 
setting. Moreover, increasing TGF-β2 levels in the CNS with intra-
thecally targeted gene therapy significantly ameliorated the chron-
ic phase of EAE. TGF-β2 is constitutively expressed by astrocytes 
in the adult CNS, and little is known about its function during neu-
roinflammation. It has been suggested that TGF-β2 plays a central 
role in the maintenance of CNS immune privilege, and downregu-
lation of astrocyte-derived TGF-β2 by T cell– and myeloid-secreted 
inflammatory cytokines appears to be a critical step for the induc-
tion and maintenance of neuroinflammation (84–86).
Altogether our data prove that increasing TGF-β signaling in 
the CNS is sufficient to interfere with differentiation and activa-
tion of MCs, which are recognized as the primary cell popula-
tion sustaining neuroinflammation and the final effectors of tis-
sue damage in CNS autoimmunity. In line with our findings, a 
recent work demonstrated that the selective deletion of TGFBRII 
in moDCs leads to the retention of moDCs in the CNS and to the 
development of more severe chronic EAE with increased irrevers-
ible tissue damage and no remission (87).
Compelling evidence demonstrates how ablating monocytes 
in the effector phases of EAE ameliorates disease progression and 
disability (35, 88). However, a phase II clinical trial with MLN1202, 
a human antibody blocking CCR2, failed to induce clinical ame-
lioration in MS patients (3). A possible explanation is that this 
antibody could mainly act via peripheral ablation of monocytes, 
many of which, at this time point, might have already migrated 
into the CNS and undergone local differentiation and activation 
(3). Instead, a successful myeloid-directed therapeutic strategy in 
established CNS autoimmunity might focus on modulating in the 
kines, including IL-23, IL12p70, TNF-α, and IL-1β, and to drive the 
differentiation of GM-CSF–producing pathogenic Th cells.
Transcriptome analyses revealed that NPC-secreted factors 
induce a profound rearrangement of chromatin organization, 
metabolism, and biosynthetic processes in myeloid cells. These 
modifications lead to the reprogramming of inflammatory DCs 
toward an alternative activation state, defined by the downregu-
lation of proinflammatory chemokines (Ccl1, Ccl2, Ccl3, Ccl7, 
Ccl8, Cxcl2) (35) and of positive regulators of cytokine produc-
tion (Cd36, refs. 36, 37; Il33, ref. 38; Clec9a, ref. 39; and Clec5a) 
and by the upregulation of tolerogenic genes, such as hepcidin 
(76), Il1r2 (41), and Ascc1 (42).
Interestingly, transcription factor analyses suggested that 
the effect of NPCs on MCs might involve the activation of c-Myc, 
c/EBPβ, and CREB1, known to control M2 polarization and MDSC 
differentiation (45, 77), as well as the inhibition of PU.1, known to 
maintain the identity and inflammatory phenotype of DCs (46, 
78). Gene set enrichment analysis confirmed that NPC treatment 
of EAE promoted in CNS-invading MCs a program of alternative 
activation via c-Myc activation and indicated TGF-β signaling as a 
possible upstream coordinator of the NPC-dependent antiinflam-
matory polarization of CNS-infiltrating MCs.
In line with our findings, a recent report has demonstrated 
that the upregulation of inhibitor of differentiation 1 (ID1), in 
response to tumor-derived factors, including TGF-β, is responsible 
for the switch from DC differentiation to MDSC expansion dur-
ing tumor progression (78). In fact, the generation of the 2 tolero-
genic myeloid cell populations, MDSCs and tumor-associated 
macrophages, in tumor-bearing hosts requires the integration of 
Figure 11. NPC-secreted TGF-β2 is nonredundant for the therapeutic 
effect. (A and B) Representative immunostainings showing similar local-
ization of GFP+ Tgfb2+/+ (A) and Tgfb2–/– (B) eNPCs (green) in meningeal 
perivascular areas in proximity to CD11b+ cells (red). Nuclei stained with 
DAPI (blue). Scale bars: 25 μm. (C) Left: Clinical scores of EAE mice treated 
with intrathecal injection of PBS (black dots), Tgfb2+/+ eNPCs (red dots), 
or Tgfb2–/– eNPCs (gray dots) at the peak of the disease (arrow) (n = 10 
mice per group). Each point represents the mean ± SEM. *P ≤ 0.05, 2-way 
ANOVA with Bonferroni’s post-test. Right: Linear regression curves from 
day of treatment (18 dpi); dashed lines indicate 95% CI. ***P ≤ 0.001. (D–F) 
Quantification of spinal cord demyelination (Luxol fast blue staining) (D), 
axonal loss (Bielschowsky silver staining) (E), and inflammatory infiltration 
(H&E staining) (F) at 60 dpi in EAE mice treated with Tgfb2–/– eNPCs (gray 
bars), Tgfb2+/+ eNPCs (white bars), and PBS (black bars) (n = 20 sections 
per mouse, 4 mice per group). Data are mean ± SEM and represent the 
percentage area of damage per total section area. *P ≤ 0.05, unpaired t 
test. (G) Flow cytometry of CNS leukocytes from EAE mice treated as in C, 
assessed at day 7 after transplantation (n = 4 mice per group). Frequencies 
of inflammatory MCs (CD45hiCD11b+Ly6G–Ly6ChiCD11c+MHC-II+) are shown in 
the plots and quantified in the graph. Black bars, PBS; white bars, Tgfb2+/+ 
eNPCs; gray bars, Tgfb2–/– eNPCs. (H) Levels of MHC-II on microglia in EAE 
mice treated with PBS (black line), Tgfb2+/+ eNPCs (red line), and Tgfb2–/– 
eNPCs (gray line) at the same time point as I are shown in the histogram 
and quantified in the graph (n = 4 per group). *P ≤ 0.05, 1-way ANOVA 
followed by Bonferroni’s post-test. (I) Confocal images and frequency of 
phospho-SMAD2+ cells over CD11b+ cells in the spinal cord of EAE mice 
treated with PBS, Tgfb2+/+ eNPCs, and Tgfb2–/– eNPCs, 7 days after treat-
ment (n = 8–12 inflammatory infiltrates per mouse; n = 3 mice per group). 
***P ≤ 0.001, 1-way ANOVA followed by Bonferroni’s post-test. Data are 
mean ± SEM and are representative of 2 independent experiments.
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Myelin antigen presentation assay. Fifty thousand BMDCs, matured 
with CD40L in vitro (10 μg/ml; R&D Systems) for 48 hours in NCM 
or DCM, were cultured in IMDM medium with 10% FCS (Genenco), 
2 mM l-glutamine (BioWhittaker), 100 U/ml penicillin, 100 mg/ml 
streptomycin (BioWhittaker), 50 mM 2-mercaptoethanol (Lonza) with 
2 × 105 CD4+ T cells isolated by CD4+ T cell MACS beads (Miltenyi Bio-
tec), according to the manufacturer’s procedures, from splenocytes of 
MOG35–55-immunized 2D2 mice at 7 dpi in the presence of MOG35–55 
peptide (20 μg/ml; Espikem) for 72 hours. DCs/CD4+ T cells were har-
vested and analyzed for cytokine production by flow cytometry.
Cytokine analysis. Multiplex quantification of cytokines and chemo-
kines in BMDC supernatant and in CNS lysates from EAE mice was per-
formed using a custom 16-plex Luminex plate (R&D Systems) accord-
ing to the manufacturer’s recommendations. Unsupervised clustering 
was performed on normalized, median-centered data and reported as 
heatmap using GENE-E software (Broad Institute). For IL23p19, GM-
CSF, TGF-β2, TNF-α, and IL-6, ELISA was performed (DuoSet ELISA 
kit, R&D Systems) according to the manufacturer’s instructions.
Gene expression microarray. Total RNA was isolated from at least 
2 × 106 BMDCs unstimulated (iDCs) or stimulated with CD40L in 
DCM (mDC) or NCM (mDC-NCM) at 6 and 18 hours of culture using 
the RNeasy Mini Kit (Qiagen). RNA quality was confirmed with a 
2100 Bioanalyzer (Agilent). cRNA amplification was performed using 
the Illumina TotalPrep RNA Amplification Kit (Ambion), and 1.5 μg 
of biotin-labeled cRNA of each sample was hybridized on Illumina 
MouseWG-6 v2 Expression BeadChip (Illumina). Data were deposited 
at ArrayExpress with the accession number E-MTAB-5307. Details on 
bioinformatics analysis are provided in Supplemental Methods.
Next-generation sequencing. C57BL/6 mice were immunized and 
treated with NPC or PBS at the peak of disease as described above. 
Seven days after transplantation, CD45hiCD11b+Ly6ChiLy6G–MHC-II+ 
MCs were FACS-sorted (BD FACSAria III) from hindbrain and spinal 
cord as described above. Total RNA from a minimum of 3 × 105 up to 
5 × 105 cells was isolated with Qiagen RNeasy Plus Micro Kit according 
to the manufacturer’s instructions. RNA quality was confirmed with 
a 2100 Bioanalyzer (Agilent) resulting in RNA integrity number ≥8. 
Amplification of cDNA from total RNA was performed using the Ova-
tion RNA-Seq system V2 (NuGEN). Then, cDNA was fragmented and 
ligated into a sequencing library using Ovation Ultralow Library System 
V2 (NuGEN). Libraries were PCR-amplified for 12 cycles and sequenced 
on an Illumina NextSeq 500 System with TruSeq reagent kits and soft-
ware. Data were deposited at the NCBI’s Gene Expression Omnibus 
(GEO) database with the accession number GSE92395. Details on bio-
informatics analysis are provided in Supplemental Methods.
EAE induction. Chronic EAE was induced in 6- to 8-week-old 
C57BL/6 female mice by s.c. immunization of MOG35–55 peptide (200 
μg per mouse) in incomplete Freund’s adjuvant containing 4 mg/ml of 
Mycobacterium tuberculosis. Pertussis toxin (500 ng) was injected i.v. at 
0 and 2 dpi. The animals were assessed daily for body weight and clini-
cal symptoms of EAE. Their disease stage was recorded by 3 research-
ers blinded to the treatment with the following scoring system (14): 0, 
healthy; 1, limp tail; 1.5, wobbling gait; 2, slight paresis of hind limbs/dif-
ficulty in righting; 2.5, severe paralysis of hind limbs; 3, complete paralysis 
of hind limbs; 3.5, initial paresis of forelimbs; 4, tetraparalysis; 5, death.
NPC intrathecal transplantation. At the treatment day, 4 days after 
clinical onset of EAE, animals were randomized into treatment groups 
and anesthetized with i.p. injection of 120–200 μl of 12.5% ketamine 
CNS the differentiation and activation of MCs, rather than ablat-
ing their entry from the periphery (3).
In conclusion, we here propose, for the first time to our knowl-
edge, a treatment able to target CNS-restricted pathogenic mech-
anisms of EAE effector phase. We identify TGF-β2 as the nonre-
dundant secreted mediator of NPC immunomodulation in the 
inflamed CNS and as a potent immunomodulatory cytokine able 
to reprogram proinflammatory MCs to antiinflammatory/sup-
pressive-like myeloid cells. The reduced amount of MC-derived 
polarizing cytokines and proinflammatory mediators in the CNS 
limits tissue damage and inhibits the terminal differentiation of 
pathogenic GM-CSF–producing Th cells. The reduction of GM-
CSF levels acts synergistically with TGF-β2 in the CNS to impair 
the effector properties of MCs, disrupting the positive-feedback 
loop sustaining leukocyte recruitment and tissue damage in EAE. 
This allows accelerated recovery and significantly less accumula-
tion of irreversible axonal loss in the chronic phase of the disease.
Methods
Mice. C57BL/6 female mice 6–8 weeks old were purchased from 
Charles River Italy. Mice with a transgene expressing T cell recep-
tor specific for MOG35–55 (2D2 mice; The Jackson Laboratory) (89) 
were provided by R. Furlan from the San Raffaele Scientific Institute. 
B6.Cg-Tg(Itgax-cre)1-1Reiz/J mice (The Jackson Laboratory) (61) 
expressing Cre recombinase under the CD11c promoter were obtained 
from M. Falcone from the San Raffaele Scientific Institute. B6;129-
Tgfbr2tm1Karl/J mice (The Jackson Laboratory) (60) were provided by 
M. Greter (University of Zürich, Zürich, Switzerland). Heterozygous 
Tgfb2tm1Doe/J mice were kindly provided by T. Doetschman (Univer-
sity of Arizona, Tucson, Arizona, USA) (62).
Adult and embryonic mouse NPC culture. Mouse NPCs were obtained 
as previously described from dissected subventricular zone of adult (6- to 
8-week-old) C57BL/6 female mice (NPCs) (14) and from dissected cortex 
of E15.5 C57BL/6 embryos (embryonic NPCs [eNPCs]) (90) from Tgfb2–/– 
and Tgfb2+/+ mice. Details are provided in Supplemental Methods.
In vitro differentiation and activation of BMDCs. BMDCs were 
prepared from bone marrow cell suspension from flushed tibias and 
femurs of naive C57BL/6 mice as previously described (91, 92). At day 
6 of in vitro culture, BMDCs were used to investigate CD40L-induced 
DC maturation: BMDCs were plated at the concentration of 2 × 106 
per milliliter in the presence of recombinant CD40L (10 μg/ml; R&D 
Systems) in DCM or NCM. In most of the experiments, BMDCs and 
culture supernatants were collected at 48 hours for FACS analysis and 
cytokine measurements, respectively. For gene expression analysis, 
BMDCs were harvested at 6 and 18 hours.
In indicated experiments the following cytokines or pharma-
cological inhibitors were added at the indicated concentrations: 
TGF-β2 (R&D Systems), SB431542 (Tocris), and ITD1 (Tocris). In a 
set of experiments, BMDCs were derived from transgenic CD11c-
Cre+Tgfbr2fl/fl, CD11c-Cre+Tgfbr2WT/WT, and CD11c-Cre–Tgfbr2fl/fl mice 
obtained by in-house breeding. Since CD11c–Cre+Tgfbr2fl/fl animals 
develop a severe, often fatal, autoimmune disease after 8 weeks of 
age, these mice were used before 8 weeks of age for ethical issues 
(60). To obtain a pure population of CD11c+ cells in which TGFBRII 
had been deleted, BMDCs derived from these latter 3 genotypes were 
FACS-sorted (Moflo XDP, Beckman Coulter) (achieving a 97% of puri-
ty) before being seeded for CD40L stimulation.
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and 6.25% xylazine in 0.9% saline solution. Animals were fixed on a 
stereotactic device (David Kopf Instruments). A 10-μl Hamilton syringe 
was loaded either with 106 NPCs, WT eNPCs, or Tgfb2–/– eNPCs dilut-
ed in 10 μl of PBS or with control vehicle solution (PBS), according to 
experimental requirements. The Hamilton syringe was then stereotac-
tically placed between the atlas and occipital bone at 35°, and advanced 
to puncture the cisterna magna. The following stereotactic coordinates 
were used: x = 0; y = –7.5 mm from λ; z = –4.5 mm from muscle plane. A 
total volume of 10 μl was injected in a 5-minute time period.
Isolation of CNS leukocytes. Extracted CNS tissue was cut into 
small pieces, incubated for 30 minutes with 0.2 mg/ml collagenase 
type IV (Sigma-Aldrich), and afterward passed through a 19G syringe 
to obtain a homogeneous cell suspension. CNS cell suspensions were 
further enriched by a Percoll gradient as previously described (93).
Flow cytometry, intracellular staining, and sorting. Flow cytometry 
was performed using a CantoII (Becton Dickinson) flow cytometer and 
analyzed with FlowJo software (Tree Star). FACS sorting was performed 
on BD FACSAria III (Becton Dickinson) or Moflo XDP (Beckman Coul-
ter). Fluorochrome-conjugated mAbs specific for mouse MHC class II 
I-A/I-E (clone M5/114.15.2), CD11b (clone M1/70), CD11c (clone N418), 
CD45 (clone 30-F11), Ly6C (clone AL-21), Ly6G (clone 1A8), CD4 (clone 
GK1.5), CD3 (clone 17A2), CD80 (clone 16-10A1), and CD86 (clone GL1) 
were purchased from either BD Biosciences, eBioscience, or Biolegend.
For intracellular staining of T cell cytokines, cells were stimulated for 
6 hours with phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin 
(500 ng/ml) in the presence of GolgiPlug (1:1,000; BD Pharmingen). 
Cells were first stained for surface molecules, fixed and permeabilized 
with a Cytofix/Cytoperm Plus kit (BD Biosciences), and stained with the 
following fluorochrome-conjugated mAbs: GM-CSF (clone MP1-22E9), 
IL-17A (clone TC11-18H10), and IFN-γ (clone XMG1.2) from BD Pharmin-
gen. For analysis of intracellular FoxP3, cell preparations were stained for 
cell surface markers, then were fixed and made permeable with fixation-
permeabilization buffers (eBioscience) and stained with fluorochrome-
conjugated anti-FoxP3 mAb (clone FJK-16s) from eBioscience.
Dead cells were always excluded using a LIVE/DEAD stain kit 
(Invitrogen).
Histopathological analyses and immunofluorescence stainings. 
Details are provided in Supplemental Methods.
Statistics. Real-time PCR data, FACS data, EAE score, and histol-
ogy results are expressed as mean ± SEM. Results were analyzed using 
the unpaired 2-tailed Student’s t test or 1-way ANOVA with Bonfer-
roni’s post-test except for clinical score, which was assessed by 2-way 
ANOVA with Bonferroni’s post-test and linear regression. Analyses 
were performed using Prism v5.0a software (GraphPad). Statistical 
significance was accepted for P less than or equal to 0.05.
Study approval. All mouse experiments were conducted with 
approval from the Institutional Animal Committee of the San Raffaele 
Scientific Institute (IACUC number 568).
Further method descriptions are provided in the Supplemental 
Methods section.
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